Risk of Serious Infection in Juvenile Idiopathic Arthritis Patients Associated With Tumor Necrosis Factor Inhibitors and Disease Activity in the German Biologics in Pediatric Rheumatology Registry

Incidence of herpes zoster infections in juvenile idiopathic arthritis patients

(2015) S. Nimmrich et al.   RHEUMATOLOGY INTERNATIONAL

Medically Significant Infections Are Increased in Patients With Juvenile Idiopathic Arthritis Treated With Etanercept: Results From the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study

(2015) Rebecca Davies et al.   Arthritis & Rheumatology

A prospective study comparing infection risk and disease activity in children with juvenile idiopathic arthritis treated with and without tumor necrosis factor-alpha inhibitors

(2014) Heather M. Walters et al.   CLINICAL RHEUMATOLOGY

Extension Study of Participants from the Trial of Early Aggressive Therapy in Juvenile Idiopathic Arthritis

(2014) C. A. Wallace et al.   JOURNAL OF RHEUMATOLOGY

Efficacy and Safety of Adalimumab as the First and Second Biologic Agent in Juvenile Idiopathic Arthritis: The German Biologics JIA Registry

(2014) Heinrike Schmeling et al.   Arthritis & Rheumatology

Etanercept treatment in juvenile idiopathic arthritis: The Polish registry

(2013) Zbigniew Zuber et al.   MEDICAL SCIENCE MONITOR

Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment

(2012) Timothy Beukelman et al.   ARTHRITIS AND RHEUMATISM

Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?

(2011) A. Strangfeld et al.   ANNALS OF THE RHEUMATIC DISEASES

Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis

(2011) Carol A. Wallace et al.   ARTHRITIS AND RHEUMATISM

2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: Initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features

(2011) Timothy Beukelman et al.   ARTHRITIS CARE & RESEARCH

Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis

(2009) E. H. Giannini et al.   ARTHRITIS AND RHEUMATISM

Development and validation of a composite disease activity score for juvenile idiopathic arthritis

(2009) Alessandro Consolaro et al.   ARTHRITIS AND RHEUMATISM

Risk of Herpes Zoster in Patients With Rheumatoid Arthritis Treated With Anti–TNF-α Agents

(2009) Anja Strangfeld   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

The Risk of Infections with Biologic Therapies for Rheumatoid Arthritis

(2009) Daniel E. Furst   SEMINARS IN ARTHRITIS AND RHEUMATISM

Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register

(2008) F H M Prince et al.   ANNALS OF THE RHEUMATIC DISEASES

Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry

(2008) G Horneff et al.   ANNALS OF THE RHEUMATIC DISEASES

Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis

(2008) Daniel J. Lovell et al.   ARTHRITIS AND RHEUMATISM

Adalimumab with or without Methotrexate in Juvenile Rheumatoid Arthritis

(2008) Daniel J. Lovell et al.   NEW ENGLAND JOURNAL OF MEDICINE